Peter Stenvinkel

List of Publications by Year in Descending Order

579 papers	32,583 citations	91 h-index	158 g-index
640 ext. papers	37,388 ext. citations	5.5 avg, IF	7.3 L-index

#	Paper	IF	Citations
579	Longitudinal genome-wide DNA methylation changes in response to kidney failure replacement therapy.. *Scientific Reports*, **2022**, 12, 470	4.9	3
578	Emerging Role of Clinical Genetics in CKD.. *Kidney Medicine*, **2022**, 4, 100435	2.8	1
577	Inflammation in chronic kidney disease **2022**, 91-105		0
576	Nutritional management of chronic peritoneal dialysis patients **2022**, 593-606		
575	Premature vascular aging and senescence in chronic kidney disease **2022**, 263-279		1
574	Osteomodulin attenuates smooth muscle cell osteogenic transition in vascular calcification.. *Clinical and Translational Medicine*, **2022**, 12, e682	5.7	1
573	Does gestational diabetes increase the risk of maternal kidney disease? A Swedish national cohort study.. *PLoS ONE*, **2022**, 17, e0264992	3.7	0
572	Blood-brain barrier and gut barrier dysfunction in chronic kidney disease with a focus on circulating biomarkers and tight junction proteins.. *Scientific Reports*, **2022**, 12, 4414	4.9	3
571	Angiotensin-converting enzyme 2 and Transmembrane protease serine 2 in female and male patients with end-stage kidney disease.. *European Journal of Clinical Investigation*, **2022**, e13786	4.6	0
570	Inhibiting BTB domain and CNC homolog 1 (Bach1) as an alternative to increase Nrf2 activation in chronic diseases.. *Biochimica Et Biophysica Acta - General Subjects*, **2022**, 130129	4	2
569	Cellular mechanisms of aging and their impact on the aortic/arterial wall **2022**, 391-405		
568	Brazil nut supplementation does not affect trimethylamine-n-oxide plasma levels in patients with coronary artery disease.. *Journal of Food Biochemistry*, **2022**, e14201	3.3	1
567	Resistant Starch Type-2 Supplementation Does Not Decrease Trimethylamine N-Oxide (TMAO) Plasma Level in Hemodialysis Patients. **2022**, 1-8		
566	Fermented food: Should patients with cardiometabolic diseases go back to an early neolithic diet?. *Critical Reviews in Food Science and Nutrition*, **2022**, 1-24	11.5	0
565	Survival on four compared with three times per week haemodialysis in high ultrafiltration patients: an observational study. *CKJ: Clinical Kidney Journal*, **2021**, 14, 665-672	4.5	2
564	High-sensitivity troponins in dialysis patients: variation and prognostic value. *CKJ: Clinical Kidney Journal*, **2021**, 14, 1789-1797	4.5	1
563	Muscle Mass Assessed by Computed Tomography at the Third Lumbar Vertebra Predicts Patient Survival in Chronic Kidney Disease. *Journal of Renal Nutrition*, **2021**, 31, 342-350	3	3

562	Sarcopenia in chronic kidney disease: what have we learned so far?. *Journal of Nephrology*, **2021**, 34, 1347-8337261	4.8	
561	Cruciferous vegetables: rationale for exploring potential salutary effects of sulforaphane-rich foods in patients with chronic kidney disease. *Nutrition Reviews*, **2021**, 79, 1204-1224	6.4	14
560	The oxygen cascade in patients treated with hemodialysis and native high-altitude dwellers: lessons from extreme physiology to benefit patients with end-stage renal disease. *American Journal of Physiology - Renal Physiology*, **2021**, 320, F249-F261	4.3	3
559	Temporal Associations Among Body Mass Index, Fasting Insulin, and Systemic Inflammation: A Systematic Review and Meta-analysis. *JAMA Network Open*, **2021**, 4, e211263	10.4	11
558	Data Sharing Under the General Data Protection Regulation: Time to Harmonize Law and Research Ethics?. *Hypertension*, **2021**, 77, 1029-1035	8.5	10
557	Methods and rationale of the DISCOVER CKD global observational study. *CKJ: Clinical Kidney Journal*, **2021**, 14, 1570-1578	4.5	1
556	Patient-Reported Measures and Lifestyle Are Associated With Deterioration in Nutritional Status in CKD Stage 4-5: The EQUAL Cohort Study. *Journal of Renal Nutrition*, **2021**,	3	2
555	A biomimetic natural sciences approach to understanding the mechanisms of ageing in burden of lifestyle diseases. *Clinical Science*, **2021**, 135, 1251-1272	6.5	1
554	Time-dependent lipid profile inversely associates with mortality in hemodialysis patients - independent of inflammation/malnutrition. *Journal of Internal Medicine*, **2021**, 290, 910-921	10.8	2
553	Inflammation and Oxidative Stress in Chronic Kidney Disease and Dialysis Patients. *Antioxidants and Redox Signaling*, **2021**, 35, 1426-1448	8.4	12
552	MO069SARS-COV-2 RECEPTOR ACE-2, TMPRSS2 AND SOLUBLE ACE-2 IN PATIENTS WITH END STAGE KIDNEY DISEASE. *Nephrology Dialysis Transplantation*, **2021**, 36,	4.3	78
551	Secular trends in hip fracture incidence and subsequent mortality in dialysis patients and the general population in Sweden. *Bone*, **2021**, 147, 115909	4.7	
550	Socioeconomic position links circulatory microbiota differences with biological age. *Scientific Reports*, **2021**, 11, 12629	4.9	3
549	A genome-wide association study suggests correlations of common genetic variants with peritoneal solute transfer rates in patients with kidney failure receiving peritoneal dialysis. *Kidney International*, **2021**, 100, 1101-1111	9.9	4
548	Potential natural immunization against atherosclerosis in hibernating bears. *Scientific Reports*, **2021** , 11, 12120	4.9	3
547	From the distinctive smell to therapeutic effects: Garlic for cardiovascular, hepatic, gut, diabetes and chronic kidney disease. *Clinical Nutrition*, **2021**, 40, 4807-4819	5.9	5
546	Classification of Uremic Toxins and Their Role in Kidney Failure. *Clinical Journal of the American Society of Nephrology: CJASN*, **2021**,	6.9	15
545	High alkaline phosphatase and low intact parathyroid hormone associate with worse clinical outcome in peritoneal dialysis patients. *Peritoneal Dialysis International*, **2021**, 41, 236-243	2.8	6

544	SARS-COV-2 and biomimetics: What saves the planet will save our health. *Journal of Internal Medicine*, **2021**, 289, 244-246	10.8	3
543	The sweet side of dark chocolate for chronic kidney disease patients. *Clinical Nutrition*, **2021**, 40, 15-26	5.9	4
542	To bee or not to bee? The bee extract propolis as a bioactive compound in the burden of lifestyle diseases. *Nutrition*, **2021**, 83, 111094	4.8	10
541	Food as medicine: targeting the uraemic phenotype in chronic kidney disease. *Nature Reviews Nephrology*, **2021**, 17, 153-171	14.9	41
540	Sparing effect of peritoneal dialysis vs hemodialysis on BMD changes and its impact on mortality. *Journal of Bone and Mineral Metabolism*, **2021**, 39, 260-269	2.9	2
539	Biomimetics provides lessons from nature for contemporary ways to improve human health. *Journal of Clinical and Translational Science*, **2021**, 5, e128	0.4	0
538	Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome. *American Journal of Nephrology*, **2021**, 52, 180-189	4.6	11
537	Inflammation, Oxidative Stress, and Bone in Chronic Kidney Disease in the Osteoimmunology Era. *Calcified Tissue International*, **2021**, 108, 452-460	3.9	5
536	Role of Uremic Toxins in Early Vascular Ageing and Calcification. *Toxins*, **2021**, 13,	4.9	5
535	Functional vitamin K insufficiency, vascular calcification and mortality in advanced chronic kidney disease: A cohort study. *PLoS ONE*, **2021**, 16, e0247623	3.7	3
534	Systematic review of the nuclear factor erythroid 2-related factor 2 (NRF2) system in human chronic kidney disease: alterations, interventions, and relation to morbidity. *Nephrology Dialysis Transplantation*, **2021**,	4.3	8
533	Recovery scenario and immunity in COVID-19 disease: A new strategy to predict the potential of reinfection. *Journal of Advanced Research*, **2021**, 31, 49-60	13	11
532	Chronic Inflammation in Chronic Kidney Disease Progression: Role of Nrf2. *Kidney International Reports*, **2021**, 6, 1775-1787	4.1	26
531	Manipulating the exposome to enable better ageing. *Biochemical Journal*, **2021**, 478, 2889-2898	3.8	4
530	Observational study of risk factors associated with clinical outcome among elderly kidney transplant recipients in Sweden - a decade of follow-up. *Transplant International*, **2021**, 34, 2363-2370	3	1
529	Reply letter- critical comments on the impact of curcumin supplementation on expression of inflammatory transcription factors in hemodialysis patients: A pilot randomized, double-blind, controlled study. *Clinical Nutrition*, **2021**, 40, 5521-5522	5.9	
528	Renal function and lipid metabolism are major predictors of circumpapillary retinal nerve fiber layer thickness-the LIFE-Adult Study. *BMC Medicine*, **2021**, 19, 202	11.4	2
527	Role of GDF-15, YKL-40 and MMP 9 in patients with end-stage kidney disease: focus on sex-specific associations with vascular outcomes and all-cause mortality. *Biology of Sex Differences*, **2021**, 12, 50	9.3	2

526	Cardiovascular Disease and Inflammation **2021**, 1-22		
525	Insights in the regulation of trimetylamine N-oxide production using a comparative biomimetic approach suggest a metabolic switch in hibernating bears. *Scientific Reports*, **2020**, 10, 20323	4.9	13
524	Can nutritional interventions modulate the activation of the NLRP3 inflammasome in chronic kidney disease?. *Food Research International*, **2020**, 136, 109306	7	7
523	Sevelamer Use in End-Stage Kidney Disease (ESKD) Patients Associates with Poor Vitamin K Status and High Levels of Gut-Derived Uremic Toxins: A Drug-Bug Interaction?. *Toxins*, **2020**, 12,	4.9	9
522	Hospitalization and mortality following non-attendance for hemodialysis according to dialysis day of the week: a European cohort study. *BMC Nephrology*, **2020**, 21, 218	2.7	4
521	Different subclasses and isotypes of antibodies against phosphorylcholine in haemodialysis patients: association with mortality. *Clinical and Experimental Immunology*, **2020**, 201, 94-104	6.2	4
520	Early vascular ageing in chronic kidney disease: impact of inflammation, vitamin K, senescence and genomic damage. *Nephrology Dialysis Transplantation*, **2020**, 35, ii31-ii37	4.3	33
519	Antibodies against Malondialdehyde in Haemodialysis Patients and Its Association with Clinical Outcomes: Differences between Subclasses and Isotypes. *Journal of Clinical Medicine*, **2020**, 9,	5.1	3
518	Copeptin is independently associated with vascular calcification in chronic kidney disease stage 5. *BMC Nephrology*, **2020**, 21, 43	2.7	3
517	Nrf2 in early vascular ageing: Calcification, senescence and therapy. *Clinica Chimica Acta*, **2020**, 505, 108-118	6.18	31
516	Aortic Valve Calcium Associates with All-Cause Mortality Independent of Coronary Artery Calcium and Inflammation in Patients with End-Stage Renal Disease. *Journal of Clinical Medicine*, **2020**, 9,	5.1	3
515	The One Health concept - the health of humans is intimately linked with the health of animals and a sustainable environment. *Journal of Internal Medicine*, **2020**, 287, 223-225	10.8	3
514	Major fractures after initiation of dialysis: Incidence, predictors and association with mortality. *Bone* , **2020**, 133, 115242	4.7	10
513	Risk of long-term renal disease in women with a history of preterm delivery: a population-based cohort study. *BMC Medicine*, **2020**, 18, 66	11.4	4
512	Impact of curcumin supplementation on expression of inflammatory transcription factors in hemodialysis patients: A pilot randomized, double-blind, controlled study. *Clinical Nutrition*, **2020**, 39, 3594-3600	5.9	32
511	Matrix Gla protein is an independent predictor of both intimal and medial vascular calcification in chronic kidney disease. *Scientific Reports*, **2020**, 10, 6586	4.9	28
510	Pro-neurotensin depends on renal function and is related to all-cause mortality in chronic kidney disease. *European Journal of Endocrinology*, **2020**, 183, 233-244	6.5	7
509	Protein-Energy Wasting/Malnutrition and the Inflammatory Response **2020**, 413-429		

508	Biomimetics - Nature's roadmap to insights and solutions for burden of lifestyle diseases. *Journal of Internal Medicine*, **2020**, 287, 238-251	10.8	21
507	Bone mineral density at different sites and 5 years mortality in end-stage renal disease patients: A cohort study. *Bone*, **2020**, 130, 115075	4.7	10
506	Fructose metabolism as a common evolutionary pathway of survival associated with climate change, food shortage and droughts. *Journal of Internal Medicine*, **2020**, 287, 252-262	10.8	34
505	Cinacalcet-induced hypocalcemia in a cohort of European haemodialysis patients: predictors, therapeutic approaches and outcomes. *Journal of Nephrology*, **2020**, 33, 803-816	4.8	3
504	Bone alkaline phosphatase: An important biomarker in chronic kidney disease - mineral and bone disorder. *Clinica Chimica Acta*, **2020**, 501, 198-206	6.2	29
503	Phenotypic features of vascular calcification in chronic kidney disease. *Journal of Internal Medicine*, **2020**, 287, 422-434	10.8	6
502	Uremic Toxins and Vascular Calcification-Missing the Forest for All the Trees. *Toxins*, **2020**, 12,	4.9	9
501	Intestinal alkaline phosphatase modulation by food components: predictive, preventive, and personalized strategies for novel treatment options in chronic kidney disease. *EPMA Journal*, **2020**, 11, 565-579	8.8	5
500	Design and methodology of the Aging Nephropathy Study (AGNES): a prospective cohort study of elderly patients with chronic kidney disease. *BMC Nephrology*, **2020**, 21, 461	2.7	2
499	Bone mineral density and mortality in end-stage renal disease patients. *CKJ: Clinical Kidney Journal*, **2020**, 13, 307-321	4.5	13
498	Incidence of Fractures Before and After Dialysis Initiation. *Journal of Bone and Mineral Research*, **2020**, 35, 2372-2380	6.3	3
497	Fractures after kidney transplantation: Incidence, predictors, and association with mortality. *Bone*, **2020**, 140, 115554	4.7	7
496	Klotho, Aging, and the Failing Kidney. *Frontiers in Endocrinology*, **2020**, 11, 560	5.7	39
495	Novel insights into the disease transcriptome of human diabetic glomeruli and tubulointerstitium. *Nephrology Dialysis Transplantation*, **2020**, 35, 2059-2072	4.3	9
494	Hypertensive disorders of pregnancy and the risk of chronic kidney disease: A Swedish registry-based cohort study. *PLoS Medicine*, **2020**, 17, e1003255	11.6	13
493	Inverse J-shaped relation between coronary arterial calcium density and mortality in advanced chronic kidney disease. *Nephrology Dialysis Transplantation*, **2020**, 35, 1202-1211	4.3	11
492	Association of changes in bone mineral parameters with mortality in haemodialysis patients: insights from the ARO cohort. *Nephrology Dialysis Transplantation*, **2020**, 35, 478-487	4.3	10
491	Dietary Patterns and Mortality in a Multinational Cohort of Adults Receiving Hemodialysis. *American Journal of Kidney Diseases*, **2020**, 75, 361-372	7.4	6

490	Understanding the role of the cytoprotective transcription factor nuclear factor erythroid 2-related factor 2-lessons from evolution, the animal kingdom and rare progeroid syndromes. *Nephrology Dialysis Transplantation*, **2020**, 35, 2036-2045	4.3	35
489	Inflammation and Premature Ageing in Chronic Kidney Disease. *Toxins*, **2020**, 12,	4.9	50
488	Adverse Pregnancy Outcomes and Long-term Maternal Kidney Disease: A Systematic Review and Meta-analysis. *JAMA Network Open*, **2020**, 3, e1920964	10.4	31
487	Hypertensive disorders of pregnancy and the risk of chronic kidney disease: A Swedish registry-based cohort study **2020**, 17, e1003255		
486	Hypertensive disorders of pregnancy and the risk of chronic kidney disease: A Swedish registry-based cohort study **2020**, 17, e1003255		
485	Hypertensive disorders of pregnancy and the risk of chronic kidney disease: A Swedish registry-based cohort study **2020**, 17, e1003255		
484	Hypertensive disorders of pregnancy and the risk of chronic kidney disease: A Swedish registry-based cohort study **2020**, 17, e1003255		
483	Hypertensive disorders of pregnancy and the risk of chronic kidney disease: A Swedish registry-based cohort study **2020**, 17, e1003255		
482	Hypertensive disorders of pregnancy and the risk of chronic kidney disease: A Swedish registry-based cohort study **2020**, 17, e1003255		
481	Associations of Chronic Inflammation, Insulin Resistance, and Severe Obesity With Mortality, Myocardial Infarction, Cancer, and Chronic Pulmonary Disease. *JAMA Network Open*, **2019**, 2, e1910456	10.4	25
480	Serum 8-hydroxydeoxyguanosine, a marker of oxidative DNA damage, is associated with mortality independent of inflammation in chronic kidney disease. *European Journal of Internal Medicine*, **2019**, 68, 60-65	3.9	13
479	Fruit and Vegetable Intake and Mortality in Adults undergoing Maintenance Hemodialysis. *Clinical Journal of the American Society of Nephrology: CJASN*, **2019**, 14, 250-260	6.9	47
478	A distinct bone phenotype in ADPKD patients with end-stage renal disease. *Kidney International*, **2019**, 95, 412-419	9.9	15
477	Early Vascular Ageing and Cellular Senescence in Chronic Kidney Disease. *Computational and Structural Biotechnology Journal*, **2019**, 17, 721-729	6.8	44
476	Cranberries - potential benefits in patients with chronic kidney disease. *Food and Function*, **2019**, 10, 3103-3112	6.1	15
475	Chemerin inhibits vascular calcification through ChemR23 and is associated with lower coronary calcium in chronic kidney disease. *Journal of Internal Medicine*, **2019**, 286, 449-457	10.8	18
474	Health-related quality of life as predictor of mortality in end-stage renal disease patients: an observational study. *BMC Nephrology*, **2019**, 20, 144	2.7	15
473	Correlation of computed tomography with carotid plaque transcriptomes associates calcification with lesion-stabilization. *Atherosclerosis*, **2019**, 288, 175-185	3.1	28

472	Serum concentration and vascular expression of adiponectin are differentially associated with the diabetic calcifying peripheral arteriopathy. *Diabetology and Metabolic Syndrome*, **2019**, 11, 32	5.6	6
471	Nutritional status of older patients on hemodialysis: Which nutritional markers can best predict clinical outcomes?. *Nutrition*, **2019**, 65, 113-119	4.8	21
470	Dietary Components That May Influence the Disturbed Gut Microbiota in Chronic Kidney Disease. *Nutrients*, **2019**, 11,	6.7	64
469	Methyl Donor Nutrients in Chronic Kidney Disease: Impact on the Epigenetic Landscape. *Journal of Nutrition*, **2019**, 149, 372-380	4.1	13
468	Senescent Cells in Early Vascular Ageing and Bone Disease of Chronic Kidney Disease-A Novel Target for Treatment. *Toxins*, **2019**, 11,	4.9	21
467	Hypoalbuminemia: a price worth paying for improved dialytic removal of middle-molecular-weight uremic toxins?. *Nephrology Dialysis Transplantation*, **2019**, 34, 901-907	4.3	11
466	Long-lived animals with negligible senescence: clues for ageing research. *Biochemical Society Transactions*, **2019**, 47, 1157-1164	5.1	16
465	Allostatic load and ageing: linking the microbiome and nutrition with age-related health. *Biochemical Society Transactions*, **2019**, 47, 1165-1172	5.1	23
464	Reduced skeletal muscle expression of mitochondrial-derived peptides humanin and MOTS-C and Nrf2 in chronic kidney disease. *American Journal of Physiology - Renal Physiology*, **2019**, 317, F1122-F1131	4.3	19
463	Preeclampsia and risk of end stage kidney disease: A Swedish nationwide cohort study. *PLoS Medicine*, **2019**, 16, e1002875	11.6	26
462	A journey from microenvironment to macroenvironment: the role of metaflammation and epigenetic changes in cardiorenal disease. *CKJ: Clinical Kidney Journal*, **2019**, 12, 861-870	4.5	8
461	Obesity in Kidney Disease **2019**, 265-275		
460	Effects of Probiotic Supplementation on Trimethylamine-N-Oxide Plasma Levels in Hemodialysis Patients: a Pilot Study **2019**, 11, 648		1
459	Differences in association of lower bone mineral density with higher coronary calcification in female and male end-stage renal disease patients. *BMC Nephrology*, **2019**, 20, 59	2.7	6
458	Whole genome DNA sequencing provides an atlas of somatic mutagenesis in healthy human cells and identifies a tumor-prone cell type. *Genome Biology*, **2019**, 20, 285	18.3	24
457	Inflammation in Chronic Kidney Disease **2019**, 208-223.e9		
456	The G-protein coupled receptor ChemR23 determines smooth muscle cell phenotypic switching to enhance high phosphate-induced vascular calcification. *Cardiovascular Research*, **2019**, 115, 1557-1566	9.9	24
455	MicroRNAs in AKI and Kidney Transplantation. *Clinical Journal of the American Society of Nephrology: CJASN*, **2019**, 14, 454-468	6.9	32

454	Mitochondrial dysfunction and gut microbiota imbalance: An intriguing relationship in chronic kidney disease. *Mitochondrion*, **2019**, 47, 206-209	4.9	10
453	Association of Serum Sclerostin with Bone Sclerostin in Chronic Kidney Disease is Lost in Glucocorticoid Treated Patients. *Calcified Tissue International*, **2019**, 104, 214-223	3.9	7
452	Effects of acute fructose loading on levels of serum uric acid-a pilot study. *European Journal of Clinical Investigation*, **2019**, 49, e13040	4.6	4
451	Circulating proteins as predictors of cardiovascular mortality in end-stage renal disease. *Journal of Nephrology*, **2019**, 32, 111-119	4.8	24
450	Dietary n-3 polyunsaturated fatty acid intake and all-cause and cardiovascular mortality in adults on hemodialysis: The DIET-HD multinational cohort study. *Clinical Nutrition*, **2019**, 38, 429-437	5.9	13
449	Skin autofluorescence, arterial stiffness and Framingham risk score as predictors of clinical outcome in chronic kidney disease patients: a cohort study. *Nephrology Dialysis Transplantation*, **2019**, 34, 442-448	4.3	16
448	Effects of Probiotic Supplementation on Trimethylamine-N-Oxide Plasma Levels in Hemodialysis Patients: a Pilot Study. *Probiotics and Antimicrobial Proteins*, **2019**, 11, 648-654	5.5	41
447	Prevalence and Risk of Protein-Energy Wasting Assessed by Subjective Global Assessment in Older Adults With Advanced Chronic Kidney Disease: Results From the EQUAL Study. *Journal of Renal Nutrition*, **2018**, 28, 165-174	3	25
446	The microbial metabolite trimethylamine-N-oxide in association with inflammation and microbial dysregulation in three HIV cohorts at various disease stages. *Aids*, **2018**, 32, 1589-1598	3.5	19
445	Lung Dysfunction and Mortality in Patients with Chronic Kidney Disease. *Kidney and Blood Pressure Research*, **2018**, 43, 522-535	3.1	12
444	Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney International*, **2018**, 93, 1281-1292	9.9	41
443	Could Low-Protein Diet Modulate Nrf2 Pathway in Chronic Kidney Disease?. *Journal of Renal Nutrition*, **2018**, 28, 229-234	3	7
442	Curcumin - A promising nutritional strategy for chronic kidney disease patients. *Journal of Functional Foods*, **2018**, 40, 715-721	5.1	33
441	Novel treatment strategies for chronic kidney disease: insights from the animal kingdom. *Nature Reviews Nephrology*, **2018**, 14, 265-284	14.9	57
440	The Association of Mediterranean and DASH Diets with Mortality in Adults on Hemodialysis: The DIET-HD Multinational Cohort Study. *Journal of the American Society of Nephrology: JASN*, **2018**, 29, 1741-1751	12.7	15
439	Do metabolic derangements in end-stage polycystic kidney disease differ versus other primary kidney diseases?. *Nephrology*, **2018**, 23, 31-36	2.2	1
438	Red meat intake in chronic kidney disease patients: Two sides of the coin. *Nutrition*, **2018**, 46, 26-32	4.8	30
437	Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients. *BMC Pharmacology & Toxicology*, **2018**, 19, 33	2.6	11

436	Restrictive lung disorder is common in patients with kidney failure and associates with protein-energy wasting, inflammation and cardiovascular disease. *PLoS ONE*, **2018**, 13, e0195585	3.7	11
435	Bioactive food and exercise in chronic kidney disease: Targeting the mitochondria. *European Journal of Clinical Investigation*, **2018**, 48, e13020	4.6	15
434	Pregnancy-associated plasma protein A and mortality in haemodialysis. *European Journal of Clinical Investigation*, **2018**, 48, e12959	4.6	
433	The higher mortality associated with low serum albumin is dependent on systemic inflammation in end-stage kidney disease. *PLoS ONE*, **2018**, 13, e0190410	3.7	54
432	The value of the Brazilian açai fruit as a therapeutic nutritional strategy for chronic kidney disease patients. *International Urology and Nephrology*, **2018**, 50, 2207-2220	2.3	9
431	High-density lipoprotein from end-stage renal disease patients exhibits superior cardioprotection and increase in sphingosine-1-phosphate. *European Journal of Clinical Investigation*, **2018**, 48, e12866	4.6	11
430	Eating During Hemodialysis Treatment: A Consensus Statement From the International Society of Renal Nutrition and Metabolism. *Journal of Renal Nutrition*, **2018**, 28, 4-12	3	43
429	Pregnancy-associated plasma protein-A predicts survival in end-stage renal disease-confounding and modifying effects of cardiovascular disease, body composition and inflammation. *Nephrology Dialysis Transplantation*, **2018**, 33, 971-977	4.3	3
428	FP634HIGH ALL CAUSE AND CVD MORTALITY IN AN INCIDENT COHORT OF HEMODIALYSIS PATIENTS WITH LOW SERUM ALBUMIN AND INFLAMMATION. *Nephrology Dialysis Transplantation*, **2018**, 33, i257-i257	4.3	
427	SP298HIGHER MEAN CORPUSCULAR VOLUME ASSOCIATES WITH POOR CLINICAL OUTCOME IN CKD5 PATIENTS. *Nephrology Dialysis Transplantation*, **2018**, 33, i444-i444	4.3	
426	FP336HIGHER NEUTROPHIL TO LYMPHOCYTE RATIO ASSOCIATES WITH POOR CLINICAL OUTCOME IN CKD5 PATIENTS. *Nephrology Dialysis Transplantation*, **2018**, 33, i144-i145	4.3	
425	SaO066THE VARIATION IN HOSPITALISATION AND MORTALITY FOLLOWING NON-ATTENDANCE FOR HAEMODIALYSIS ACCORDING TO DIALYSIS DAY OF THE WEEK IN A EUROPEAN COHORT: FURTHER EVIDENCE OF HARM FROM THE TWO-DAY BREAK IN THREE TIMES A WEEK HAEMODIALYSIS. *Nephrology Dialysis Transplantation*, **2018**, 33, i241-i241	4.3	1
424	SaO027CHANGES IN BONE-MINERAL PARAMETERS PREDICT SUBSEQUENT MORTALITY IN HEMODIALYSIS PATIENTS - INSIGHTS FROM THE EUROPEAN ARO-COHORT. *Nephrology Dialysis Transplantation*, **2018**, 33, i326-i326	4.3	
423	Serum Glutaredoxin Activity as a Marker of Oxidative Stress in Chronic Kidney Disease: A Pilot Study. *Nephron*, **2018**, 140, 249-256	3.3	6
422	FP630ASSOCIATION OF FRUIT AND VEGETABLE INTAKE WITH ALL-CAUSE MORTALITY IN HEMODIALYSIS PATIENTS (DIET-HD): A PROSPECTIVE COHORT STUDY. *Nephrology Dialysis Transplantation*, **2018**, 33, i255-i25‘ 6	4.3	1
421	Chronic inflammation in end-stage renal disease and dialysis. *Nephrology Dialysis Transplantation*, **2018**, 33, iii35-iii40	4.3	113
420	SP323HIGH FIBRINOGEN LEVELS ARE INDEPENDENTLY ASSOCIATED WITH INCREASED MORTALITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD). *Nephrology Dialysis Transplantation*, **2018**, 33, i452-i452	4.3	
419	Effects of probiotic supplementation on inflammatory biomarkers and uremic toxins in non-dialysis chronic kidney patients: A double-blind, randomized, placebo-controlled trial. *Journal of Functional Foods*, **2018**, 46, 378-383	5.1	15

418	FP662THE ASSOCIATION OF MEDITERRANEAN AND DASH DIETS WITH MORTALITY IN ADULTS ON HEMODIALYSIS: THE DIET-HD MULTINATIONAL COHORT STUDY. *Nephrology Dialysis Transplantation*, **2018**, 33, i268-i268	4.3	
417	Total and bone-specific alkaline phosphatase are associated with bone mineral density over time in end-stage renal disease patients starting dialysis. *Journal of Nephrology*, **2017**, 30, 255-262	4.8	19
416	Circulating markers of ageing and allostatic load: A slow train coming. *Practical Laboratory Medicine* , **2017**, 7, 49-54	1.7	31
415	Sclerostin-A Debutant on the Autosomal Dominant Polycystic Kidney Disease Scene?. *Kidney International Reports*, **2017**, 2, 481-485	4.1	5
414	Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. *Lancet, The*, **2017**, 390, 1888-1917	40	419
413	Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD. *Nature Reviews Nephrology*, **2017**, 13, 429-442	14.9	130
412	Inflamed fat and mitochondrial dysfunction in end-stage renal disease links to hypoxia-could curcumin be of benefit?. *Nephrology Dialysis Transplantation*, **2017**, 32, 909-912	4.3	7
411	The role of epigenetics in renal ageing. *Nature Reviews Nephrology*, **2017**, 13, 471-482	14.9	62
410	Nonpharmacologic Strategies to Modulate Nuclear Factor Erythroid 2-related Factor 2 Pathway in Chronic Kidney Disease. *Journal of Renal Nutrition*, **2017**, 27, 282-291	3	13
409	Bone mineral density of extremities is associated with coronary calcification and biopsy-verified vascular calcification in living-donor renal transplant recipients. *Journal of Bone and Mineral Metabolism*, **2017**, 35, 536-543	2.9	7
408	Does statins promote vascular calcification in chronic kidney disease?. *European Journal of Clinical Investigation*, **2017**, 47, 137-148	4.6	48
407	Genetic and environmental risk factors for chronic kidney disease. *Kidney International Supplements* , **2017**, 7, 88-106	6.3	28
406	Strategies to improve monitoring disease progression, assessing cardiovascular risk, and defining prognostic biomarkers in chronic kidney disease. *Kidney International Supplements*, **2017**, 7, 107-113	6.3	17
405	Inflammation and premature aging in advanced chronic kidney disease. *American Journal of Physiology - Renal Physiology*, **2017**, 313, F938-F950	4.3	121
404	Plasma Beta-Trace Protein as a Marker of Residual Renal Function: The Effect of Different Hemodialysis Modalities and Intra-Individual Variability over Time. *Kidney and Blood Pressure Research*, **2017**, 42, 877-885	3.1	8
403	Renal volumetry with magnetic resonance imaging. *Acta Radiologica Open*, **2017**, 6, 2058460117731120	1.2	4
402	Current epigenetic aspects the clinical kidney researcher should embrace. *Clinical Science*, **2017**, 131, 1649-1667	6.5	9
401	Rare progerin-expressing preadipocytes and adipocytes contribute to tissue depletion over time. *Scientific Reports*, **2017**, 7, 4405	4.9	17

400	Inflamed fat and mitochondrial dysfunction in end-stage renal disease links to hypoxia-could curcumin be of benefit?. *Nephrology Dialysis Transplantation*, **2017**, 32, 1263	4.3	3
399	Inflammation and Protein-Energy Wasting in the Uremic Milieu. *Contributions To Nephrology*, **2017**, 191, 58-71	1.6	47
398	Clinical global assessment of nutritional status as predictor of mortality in chronic kidney disease patients. *PLoS ONE*, **2017**, 12, e0186659	3.7	35
397	expression is associated with vascular progeria in chronic kidney disease. *Aging*, **2017**, 9, 494-507	5.6	40
396	Prognostic Value of Copeptin in Chronic Kidney Disease: From General Population to End-Stage Renal Disease. *Current Protein and Peptide Science*, **2017**, 18, 1232-1243	2.8	4
395	Therapeutics targeting persistent inflammation in chronic kidney disease. *Translational Research*, **2016**, 167, 204-13	11	70
394	Muscle wasting in end-stage renal disease promulgates premature death: established, emerging and potential novel treatment strategies. *Nephrology Dialysis Transplantation*, **2016**, 31, 1070-7	4.3	94
393	Sex and gender differences in chronic kidney disease: progression to end-stage renal disease and haemodialysis. *Clinical Science*, **2016**, 130, 1147-63	6.5	112
392	Increased Telomere Attrition After Renal Transplantation-Impact of Antimetabolite Therapy. *Transplantation Direct*, **2016**, 2, e116	2.3	12
391	Biomarkers of Cardiovascular Disease and Mortality Risk in Patients with Advanced CKD. *Clinical Journal of the American Society of Nephrology: CJASN*, **2016**, 11, 1163-72	6.9	91
390	Metabolic and Kidney Diseases in the Setting of Climate Change, Water Shortage, and Survival Factors. *Journal of the American Society of Nephrology: JASN*, **2016**, 27, 2247-56	12.7	42
389	A cohort study of insulin-like growth factor 1 and mortality in haemodialysis patients. *CKJ: Clinical Kidney Journal*, **2016**, 9, 148-52	4.5	10
388	Association between levels of pentraxin 3 and incidence of chronic kidney disease in the elderly. *Journal of Internal Medicine*, **2016**, 279, 173-9	10.8	18
387	Telomere Attrition and Elongation after Chronic Dialysis Initiation in Patients with End-Stage Renal Disease. *Blood Purification*, **2016**, 41, 25-33	3.1	8
386	Inflammation Modifies the Paradoxical Association between Body Mass Index and Mortality in Hemodialysis Patients. *Journal of the American Society of Nephrology: JASN*, **2016**, 27, 1479-86	12.7	70
385	Serum Trimethylamine-N-Oxide Is Strongly Related to Renal Function and Predicts Outcome in Chronic Kidney Disease. *PLoS ONE*, **2016**, 11, e0141738	3.7	185
384	Plasma Pentosidine and Its Association with Mortality in Patients with Chronic Kidney Disease. *PLoS ONE*, **2016**, 11, e0163826	3.7	22
383	Accelerated ageing and renal dysfunction links lower socioeconomic status and dietary phosphate intake. *Aging*, **2016**, 8, 1135-49	5.6	42

382	SP242GLOMERULAR FILTRATION RATE ESTIMATION USING BETA TRACE PROTEIN: EXTERNAL VALIDATION OF THREE EQUATIONS. *Nephrology Dialysis Transplantation*, **2016**, 31, i167-i167	4.3	
381	SP286PLASMA BETA TRACE PROTEIN PREDICTS MORTALITY IN CKD: RELATION WITH ENDOTHELIAL DYSFUNCTION. *Nephrology Dialysis Transplantation*, **2016**, 31, i183-i184	4.3	
380	MP528SKIN AUTOFLUORESCENCE (SAF), A MARKER OF TISSUE ADVANCED GLYCATED END-PRODUCTS (AGE), AND ARTERIAL STIFFNESS IN PERITONEAL DIALYSIS PATIENTS. *Nephrology Dialysis Transplantation*, **2016**, 31, i516-i516	4.3	
379	Nutrients and ageing: what can we learn about ageing interactions from animal biology?. *Current Opinion in Clinical Nutrition and Metabolic Care*, **2016**, 19, 19-25	3.8	13
378	Dialysis modality and nutritional status are associated with variability of inflammatory markers. *Nephrology Dialysis Transplantation*, **2016**, 31, 1320-7	4.3	30
377	Genotypic and phenotypic predictors of inflammation in patients with chronic kidney disease. *Nephrology Dialysis Transplantation*, **2016**, 31, 2033-2040	4.3	8
376	Climate Change and the Emergent Epidemic of CKD from Heat Stress in Rural Communities: The Case for Heat Stress Nephropathy. *Clinical Journal of the American Society of Nephrology: CJASN*, **2016**, 11, 1472-83	6.9	185
375	Development and validation of cardiovascular risk scores for haemodialysis patients. *International Journal of Cardiology*, **2016**, 216, 68-77	3.2	30
374	Elevated Circulating S100A12 Associates with Vascular Disease and Worse Clinical Outcome in Peritoneal Dialysis Patients. *Peritoneal Dialysis International*, **2016**, 36, 269-76	2.8	7
373	Screening for muscle wasting and dysfunction in patients with chronic kidney disease. *Kidney International*, **2016**, 90, 53-66	9.9	141
372	Vertebral bone density associates with coronary artery calcification and is an independent predictor of poor outcome in end-stage renal disease patients. *Bone*, **2016**, 92, 50-57	4.7	27
371	Implantation of Autologous Selected Renal Cells in Diabetic Chronic Kidney Disease Stages 3 and 4-Clinical Experience of a "First in Human" Study. *Kidney International Reports*, **2016**, 1, 105-113	4.1	8
370	Oxidative DNA damage and mortality in hemodialysis and peritoneal dialysis patients. *Peritoneal Dialysis International*, **2015**, 35, 206-15	2.8	29
369	Regional variations in the relationship between arterial stiffness and adipocyte volume or number in obese subjects. *International Journal of Obesity*, **2015**, 39, 222-7	5.5	25
368	Serum hepatocyte growth factor is associated with truncal fat mass and increased mortality in chronic kidney disease stage 5 patients with protein-energy wasting. *Nephrology Dialysis Transplantation*, **2015**, 30, 274-82	4.3	9
367	High levels of soluble tumor necrosis factor receptors 1 and 2 and their association with mortality in patients undergoing hemodialysis. *CardioRenal Medicine*, **2015**, 5, 89-95	2.8	12
366	Vascular Effects of Inflammation and Oxidative Stress in CKD **2015**, 51-59		
365	Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. *Kidney International*, **2015**, 88, 1356-1364	9.9	83

364	Increased Levels of Modified Advanced Oxidation Protein Products Are Associated with Central and Peripheral Blood Pressure in Peritoneal Dialysis Patients. *Peritoneal Dialysis International*, **2015**, 35, 460-70	2.8	14
363	High cardiovascular event rates occur within the first weeks of starting hemodialysis. *Kidney International*, **2015**, 88, 1117-25	9.9	74
362	Obesity--a disease with many aetiologies disguised in the same oversized phenotype: has the overeating theory failed?. *Nephrology Dialysis Transplantation*, **2015**, 30, 1656-64	4.3	17
361	Premature aging in chronic kidney disease and chronic obstructive pulmonary disease: similarities and differences. *Current Opinion in Clinical Nutrition and Metabolic Care*, **2015**, 18, 528-34	3.8	7
360	Opposing activity changes in AMP deaminase and AMP-activated protein kinase in the hibernating ground squirrel. *PLoS ONE*, **2015**, 10, e0123509	3.7	30
359	Endostatin, Cathepsin S, and Cathepsin L, and Their Association with Inflammatory Markers and Mortality in Patients Undergoing Hemodialysis. *Blood Purification*, **2015**, 39, 259-65	3.1	11
358	Clinical determinants of reduced physical activity in hemodialysis and peritoneal dialysis patients. *Journal of Nephrology*, **2015**, 28, 503-10	4.8	33
357	Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients. *Nephrology Dialysis Transplantation*, **2015**, 30, 84-91	4.3	44
356	Epicardial fat accumulation, cardiometabolic profile and cardiovascular events in patients with stages 3-5 chronic kidney disease. *Journal of Internal Medicine*, **2015**, 278, 77-87	10.8	26
355	Associations between Thyroid Hormones, Calcification Inhibitor Levels and Vascular Calcification in End-Stage Renal Disease. *PLoS ONE*, **2015**, 10, e0132353	3.7	23
354	Serum fatty acid patterns, insulin sensitivity and the metabolic syndrome in individuals with chronic kidney disease. *Journal of Internal Medicine*, **2014**, 275, 71-83	10.8	29
353	Chronic kidney disease and premature ageing. *Nature Reviews Nephrology*, **2014**, 10, 732-42	14.9	215
352	Subclinical atherosclerosis, endothelial function, and serum inflammatory markers in chronic kidney disease stages 3 to 4. *Angiology*, **2014**, 65, 443-9	2.1	13
351	Clinical correlates of insulin sensitivity and its association with mortality among men with CKD stages 3 and 4. *Clinical Journal of the American Society of Nephrology: CJASN*, **2014**, 9, 690-7	6.9	37
350	Serum testosterone levels and clinical outcomes in male hemodialysis patients. *American Journal of Kidney Diseases*, **2014**, 63, 268-75	7.4	38
349	Selection of genetic and phenotypic features associated with inflammatory status of patients on dialysis using relaxed linear separability method. *PLoS ONE*, **2014**, 9, e86630	3.7	4
348	Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol. *Nephrology Dialysis Transplantation*, **2014**, 29, 1633-8	4.3	54
347	How can genetics and epigenetics help the nephrologist improve the diagnosis and treatment of chronic kidney disease patients?. *Nephrology Dialysis Transplantation*, **2014**, 29, 972-80	4.3	12

346	The relationship between IL-10 levels and cardiovascular events in patients with CKD. *Clinical Journal of the American Society of Nephrology: CJASN*, **2014**, 9, 1207-16	6.9	36
345	IGF-1 and survival in ESRD. *Clinical Journal of the American Society of Nephrology: CJASN*, **2014**, 9, 120-7	6.9	25
344	Validation of insulin sensitivity surrogate indices and prediction of clinical outcomes in individuals with and without impaired renal function. *Kidney International*, **2014**, 86, 383-91	9.9	30
343	Novel insights from genetic and epigenetic studies in understanding the complex uraemic phenotype. *Nephrology Dialysis Transplantation*, **2014**, 29, 964-71	4.3	9
342	Inflammatory biomarker pentraxin 3 (PTX3) in relation to obesity, body fat depots and weight loss. *Obesity*, **2014**, 22, 1373-9	8	35
341	Delta-He: a novel marker of inflammation predicting mortality and ESA response in peritoneal dialysis patients. *CKJ: Clinical Kidney Journal*, **2014**, 7, 275-81	4.5	4
340	Determinants of N-terminal pro-brain natriuretic peptide variation in hemodialysis patients and prediction of survival. *Blood Purification*, **2014**, 37, 138-45	3.1	7
339	Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. *JAMA - Journal of the American Medical Association*, **2014**, 311, 919-28	27.4	104
338	Comparative associations of muscle mass and muscle strength with mortality in dialysis patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2014**, 9, 1720-8	6.9	259
337	Three-month variation of plasma pentraxin 3 compared with C-reactive protein, albumin and homocysteine levels in haemodialysis patients. *CKJ: Clinical Kidney Journal*, **2014**, 7, 373-9	4.5	4
336	Low serum testosterone is associated with atherosclerosis in postmenopausal women undergoing hemodialysis. *Clinical and Experimental Nephrology*, **2014**, 18, 499-506	2.5	10
335	Why cachexia kills: examining the causality of poor outcomes in wasting conditions. *Journal of Cachexia, Sarcopenia and Muscle*, **2013**, 4, 89-94	10.3	94
334	Nonthyroidal illness and the cardiorenal syndrome. *Nature Reviews Nephrology*, **2013**, 9, 599-609	14.9	30
333	Kidney biomimicry--a rediscovered scientific field that could provide hope to patients with kidney disease. *Archives of Medical Research*, **2013**, 44, 584-90	6.6	8
332	Obesity and nephrology: results of a knowledge and practice pattern survey. *Nephrology Dialysis Transplantation*, **2013**, 28 Suppl 4, iv99-104	4.3	26
331	Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). *Journal of Renal Nutrition*, **2013**, 23, 77-90	3	407
330	Hibernating bears (Ursidae): metabolic magicians of definite interest for the nephrologist. *Kidney International*, **2013**, 83, 207-12	9.9	39
329	Clinical determinants and mortality predictability of stearoyl-CoA desaturase-1 activity indices in dialysis patients. *Journal of Internal Medicine*, **2013**, 273, 263-72	10.8	9

328	Self-rated appetite as a predictor of mortality in patients with stage 5 chronic kidney disease. *Journal of Renal Nutrition*, **2013**, 23, 106-13	3	16
327	Endogenous testosterone, muscle strength, and fat-free mass in men with chronic kidney disease. *Journal of Renal Nutrition*, **2013**, 23, e89-95	3	42
326	Can treating persistent inflammation limit protein energy wasting?. *Seminars in Dialysis*, **2013**, 26, 16-9	2.5	17
325	Uremic Toxicity **2013**, 49-77		5
324	Nutritional strategies to modulate inflammation and oxidative stress pathways via activation of the master antioxidant switch Nrf2. *Biochimie*, **2013**, 95, 1525-33	4.6	124
323	Redefining metabolic syndrome as a fat storage condition based on studies of comparative physiology. *Obesity*, **2013**, 21, 659-64	8	43
322	Chronic kidney disease: a clinical model of premature aging. *American Journal of Kidney Diseases*, **2013**, 62, 339-51	7.4	184
321	Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism. *Kidney International*, **2013**, 84, 1096-107	9.9	348
320	Determinants of fibroblast growth factor-23 and parathyroid hormone variability in dialysis patients. *American Journal of Nephrology*, **2013**, 37, 462-71	4.6	9
319	Subclinical versus overt obesity in dialysis patients: more than meets the eye. *Nephrology Dialysis Transplantation*, **2013**, 28 Suppl 4, iv175-81	4.3	20
318	Inflammation in Chronic Kidney Disease **2013**, 79-91		
317	Anorexia and Appetite Stimulants in Chronic Kidney Disease **2013**, 645-657		2
316	Evaluation of the association of plasma pentraxin 3 levels with type 2 diabetes and diabetic nephropathy in a Malay population. *Journal of Diabetes Research*, **2013**, 2013, 298019	3.9	13
315	Differences in acute metabolism of fructose between hemodialysis patients and healthy subjects. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2013**, 73, 154-60	2	7
314	Obesity in CKD--what should nephrologists know?. *Journal of the American Society of Nephrology: JASN*, **2013**, 24, 1727-36	12.7	134
313	Effects of hemodiafiltration on uremic inflammation. *Blood Purification*, **2013**, 35 Suppl 1, 11-7	3.1	14
312	Research update for articles published in EJCI in 2011. *European Journal of Clinical Investigation*, **2013**, 43, 1097-1110	4.6	2
311	Nonthyroidal illness: a risk factor for coronary calcification and arterial stiffness in patients undergoing peritoneal dialysis?. *Journal of Internal Medicine*, **2013**, 274, 584-93	10.8	27

310	Immunoglobulin (Ig)M antibodies against oxidized cardiolipin but not native cardiolipin are novel biomarkers in haemodialysis patients, associated negatively with mortality. *Clinical and Experimental Immunology*, **2013**, 174, 441-8	6.2	4
309	Circulating vascular endothelial growth factor (VEGF) and its soluble receptor 1 (sVEGFR-1) are associated with inflammation and mortality in incident dialysis patients. *Nephrology Dialysis Transplantation*, **2013**, 28, 2356-63	4.3	34
308	Dietary fat modification in patients with chronic kidney disease: n-3 fatty acids and beyond. *Journal of Nephrology*, **2013**, 26, 960-74	4.8	27
307	Effects of dopamine on leptin release and leptin gene (OB) expression in adipocytes from obese and hypertensive patients. *International Journal of Nephrology and Renovascular Disease*, **2013**, 6, 259-68	2.5	4
306	Metabolic changes in summer active and anuric hibernating free-ranging brown bears (Ursus arctos). *PLoS ONE*, **2013**, 8, e72934	3.7	36
305	Resveratrol: why is it a promising therapy for chronic kidney disease patients?. *Oxidative Medicine and Cellular Longevity*, **2013**, 2013, 963217	6.7	45
304	Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction. *PLoS ONE*, **2013**, 8, e63493	3.7	35
303	Determinants and survival implications of low bone mineral density in end-stage renal disease patients. *Journal of Nephrology*, **2013**, 26, 485-94	4.8	19
302	Cardiovascular biomarkers in chronic kidney disease. *Journal of Renal Nutrition*, **2012**, 22, 120-7	3	21
301	Plasma fatty acids in chronic kidney disease: nervonic acid predicts mortality. *Journal of Renal Nutrition*, **2012**, 22, 277-283	3	22
300	The complex role of adiponectin in chronic kidney disease. *Biochimie*, **2012**, 94, 2150-6	4.6	38
299	Essential polyunsaturated fatty acids, inflammation and mortality in dialysis patients. *Nephrology Dialysis Transplantation*, **2012**, 27, 3615-20	4.3	38
298	Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation. *European Journal of Clinical Pharmacology*, **2012**, 68, 571-7	2.8	18
297	Hypogonadism in males with chronic kidney disease: another cause of resistance to erythropoiesis-stimulating agents?. *Contributions To Nephrology*, **2012**, 178, 35-39	1.6	4
296	The vulnerable man: impact of testosterone deficiency on the uraemic phenotype. *Nephrology Dialysis Transplantation*, **2012**, 27, 4030-41	4.3	60
295	Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. *Clinical Journal of the American Society of Nephrology: CJASN*, **2012**, 7, 207-15	6.9	67
294	Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease. *Nephrology Dialysis Transplantation*, **2012**, 27, 709-15	4.3	59
293	Baseline levels and trimestral variation of triiodothyronine and thyroxine and their association with mortality in maintenance hemodialysis patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2012**, 7, 131-8	6.9	40

292	Serum albumin as predictor of nutritional status in patients with ESRD. *Clinical Journal of the American Society of Nephrology: CJASN*, **2012**, 7, 1446-53	6.9	109
291	Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease. *Nephrology Dialysis Transplantation*, **2012**, 27, 70-5	4.3	80
290	DNA hypermethylation and inflammatory markers in incident Japanese dialysis patients. *Nephron Extra*, **2012**, 2, 159-68		15
289	Mechanisms of endothelial dysfunction in resistance arteries from patients with end-stage renal disease. *PLoS ONE*, **2012**, 7, e36056	3.7	30
288	Genetic studies in chronic kidney disease: basic concepts. *Journal of Nephrology*, **2012**, 25, 141-9	4.8	3
287	Genetic studies in chronic kidney disease: interpretation and clinical applicability. *Journal of Nephrology*, **2012**, 25, 851-64	4.8	6
286	Activity-related energy expenditure of patients undergoing hemodialysis. *Journal of Renal Nutrition* , **2011**, 21, 226-34	3	22
285	Adiponectin in chronic kidney disease: a complex and context sensitive clinical situation. *Journal of Renal Nutrition*, **2011**, 21, 82-6	3	37
284	Influence of erythropoiesis-stimulating agents on glycated hemoglobin in nondiabetic kidney diseases at the start of dialysis. *American Journal of Nephrology*, **2011**, 33, 17-24	4.6	5
283	TNF- levels are not increased in inflamed patients carrying the CCR5 deletion 32. *Cytokine*, **2011**, 53, 16-8	4	7
282	Inflammation as a risk factor and target for therapy in chronic kidney disease. *Current Opinion in Nephrology and Hypertension*, **2011**, 20, 662-8	3.5	80
281	Expression of osteoprotegerin in human fat tissue; implications for chronic kidney disease. *European Journal of Clinical Investigation*, **2011**, 41, 498-506	4.6	12
280	Increased expression of pro-inflammatory genes in abdominal subcutaneous fat in advanced chronic kidney disease patients. *Journal of Internal Medicine*, **2011**, 269, 410-9	10.8	37
279	Wasting in chronic kidney disease. *Journal of Cachexia, Sarcopenia and Muscle*, **2011**, 2, 9-25	10.3	160
278	Predialysis chronic kidney disease in 2010: Novel targets for slowing CKD progression. *Nature Reviews Nephrology*, **2011**, 7, 65-6	14.9	5
277	Diets and enteral supplements for improving outcomes in chronic kidney disease. *Nature Reviews Nephrology*, **2011**, 7, 369-84	14.9	119
276	Is fetuin-A a mortality risk factor in dialysis patients or a mere risk marker? A Mendelian randomization approach. *Nephrology Dialysis Transplantation*, **2011**, 26, 239-45	4.3	22
275	Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor- are similarly associated with survival in haemodialysis patients. *Nephrology Dialysis Transplantation*, **2011**, 26, 1313-8	4.3	60

274	Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes. *Nephrology Dialysis Transplantation*, **2011**, 26, 3537-43	4.3	87
273	Monitoring of inflammation in patients on dialysis: forewarned is forearmed. *Nature Reviews Nephrology*, **2011**, 7, 166-76	14.9	84
272	Systemic consequences of poor oral health in chronic kidney disease patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2011**, 6, 218-26	6.9	91
271	Circulating follistatin in patients with chronic kidney disease: implications for muscle strength, bone mineral density, inflammation, and survival. *Clinical Journal of the American Society of Nephrology: CJASN*, **2011**, 6, 1001-8	6.9	24
270	Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. *Nephrology Dialysis Transplantation*, **2011**, 26, 184-90	4.3	109
269	An epidemiological study of hemodialysis patients based on the European Fresenius Medical Care hemodialysis network: results of the ARO study. *Nephron Clinical Practice*, **2011**, 118, c143-54		18
268	Inverse relationship between the inflammatory marker pentraxin-3, fat body mass, and abdominal obesity in end-stage renal disease. *Clinical Journal of the American Society of Nephrology: CJASN*, **2011**, 6, 2785-91	6.9	39
267	Postprandial metabolic response to a fat- and carbohydrate-rich meal in patients with chronic kidney disease. *Nephrology Dialysis Transplantation*, **2011**, 26, 2231-7	4.3	14
266	Uraemic sera stimulate lipolysis in human adipocytes: role of perilipin. *Nephrology Dialysis Transplantation*, **2011**, 26, 2485-91	4.3	18
265	Low cholesterol in dialysis patients--causal factor for mortality or an effect of confounding?. *Nephrology Dialysis Transplantation*, **2011**, 26, 3325-31	4.3	24
264	Like total ghrelin, acylated ghrelin is also lower in HD patients with cardiovascular disease. *Kidney International*, **2011**, 80, 783-784	9.9	
263	Protein-energy wasting modifies the association of ghrelin with inflammation, leptin, and mortality in hemodialysis patients. *Kidney International*, **2011**, 79, 749-56	9.9	49
262	Association with Helicobacter pylori infection and ghrelin level in hemodialysis patients. *Kidney International*, **2011**, 80, 894	9.9	
261	Recent insights in inflammation-associated wasting in patients with chronic kidney disease. *Contributions To Nephrology*, **2011**, 171, 120-126	1.6	29
260	Impaired resistance artery function in patients with end-stage renal disease. *Clinical Science*, **2011**, 120, 525-36	6.5	30
259	Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. *Clinical Journal of the American Society of Nephrology: CJASN*, **2011**, 6, 1617-25	6.9	83
258	Dialysis in 2011: Can cardiovascular risk in dialysis patients be decreased?. *Nature Reviews Nephrology*, **2011**, 8, 72-4	14.9	6
257	Endocrine Aspects of Chronic Kidney Disease **2011**, 2122-2137		1

256	Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. *Journal of Internal Medicine*, **2010**, 268, 456-67	10.8	229
255	Research update for articles published in EJCI in 2008. *European Journal of Clinical Investigation*, **2010**, 40, 770-789	4.6	0
254	Simple advice on lifestyle habits and long-term changes in biomarkers of inflammation and vascular adhesion in healthy middle-aged men. *European Journal of Clinical Nutrition*, **2010**, 64, 1450-6	5.2	13
253	Genetic loci influencing kidney function and chronic kidney disease. *Nature Genetics*, **2010**, 42, 373-5	36.3	205
252	Abdominal fat deposition is associated with increased inflammation, protein-energy wasting and worse outcome in patients undergoing haemodialysis. *Nephrology Dialysis Transplantation*, **2010**, 25, 562-8	4.3	94
251	Hemoglobin variability does not predict mortality in European hemodialysis patients. *Journal of the American Society of Nephrology: JASN*, **2010**, 21, 1765-75	12.7	262
250	Cardiovascular Disease in Chronic Kidney Disease **2010**, 935-950		4
249	Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2010**, 5, 2213-9	6.9	66
248	Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels. *Nephrology Dialysis Transplantation*, **2010**, 25, 901-6	4.3	44
247	Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship?. *Nephrology Dialysis Transplantation*, **2010**, 25, 3033-8	4.3	61
246	Variations in C-reactive protein during a single haemodialysis session do not associate with mortality. *Nephrology Dialysis Transplantation*, **2010**, 25, 3717-23	4.3	15
245	Clinical importance of an elevated circulating chemerin level in incident dialysis patients. *Nephrology Dialysis Transplantation*, **2010**, 25, 4017-23	4.3	35
244	Serum soluble CD36, assessed by a novel monoclonal antibody-based sandwich ELISA, predicts cardiovascular mortality in dialysis patients. *Clinica Chimica Acta*, **2010**, 411, 2079-82	6.2	27
243	The emerging pleiotrophic role of adipokines in the uremic phenotype. *Current Opinion in Nephrology and Hypertension*, **2010**, 19, 37-42	3.5	42
242	Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease. *European Journal of Clinical Pharmacology*, **2010**, 66, 269-73	2.8	9
241	Inflammation in end-stage renal disease--what have we learned in 10 years?. *Seminars in Dialysis*, **2010**, 23, 498-509	2.5	213
240	Inflammation as a target for improving health in chronic kidney disease. *F1000 Medicine Reports*, **2010**, 2, 88		3
239	Cardiovascular Disease Risk Factors in Chronic Kidney Disease: Traditional, Nontraditional, and Uremia-related Threats **2010**, 91-104		3

238	Low serum testosterone increases mortality risk among male dialysis patients. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 613-20	12.7	138
237	Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. *Clinical Journal of the American Society of Nephrology: CJASN*, **2009**, 4 Suppl 1, S49-55	6.9	137
236	Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness **2009**, 2, i18-i26		54
235	Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2009**, 4, 110-8	6.9	93
234	Low serum uric acid level is a risk factor for death in incident hemodialysis patients. *American Journal of Nephrology*, **2009**, 29, 79-85	4.6	72
233	Systemic and local inflammation in peritoneal dialysis: mechanisms, biomarkers and effects on outcome. *Contributions To Nephrology*, **2009**, 163, 132-139	1.6	9
232	Serum retinol-binding protein concentration and its association with components of the uremic metabolic syndrome in nondiabetic patients with chronic kidney disease stage 5. *American Journal of Nephrology*, **2009**, 29, 447-53	4.6	17
231	N-terminal pro-brain natriuretic peptide independently predicts protein energy wasting and is associated with all-cause mortality in prevalent HD patients. *American Journal of Nephrology*, **2009**, 29, 516-23	4.6	16
230	Adiponectin in chronic kidney disease: Dr Jekyll and Mr Hyde. *Kidney International*, **2009**, 75, 120-1; author reply 121	9.9	1
229	Low levels of IgM antibodies against phosphorylcholine-A increase mortality risk in patients undergoing haemodialysis. *Nephrology Dialysis Transplantation*, **2009**, 24, 3454-60	4.3	24
228	Associations of VEGF and its receptors sVEGFR-1 and -2 with cardiovascular disease and survival in prevalent haemodialysis patients. *Nephrology Dialysis Transplantation*, **2009**, 24, 3468-73	4.3	21
227	CCR5 deletion protects against inflammation-associated mortality in dialysis patients. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 1641-9	12.7	59
226	Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria. *Clinical Journal of the American Society of Nephrology: CJASN*, **2009**, 4, 535-41	6.9	54
225	Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival. *American Journal of Kidney Diseases*, **2009**, 53, 1024-33	7.4	94
224	Temporal discrepancies in the association between the apoB/apoA-I ratio and mortality in incident dialysis patients. *Journal of Internal Medicine*, **2009**, 265, 708-16	10.8	17
223	Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endothelial damage?. *Clinical Transplantation*, **2009**, 23, 241-8	3.8	40
222	The role of EUTox in uremic toxin research. *Seminars in Dialysis*, **2009**, 22, 323-8	2.5	25
221	Hyperhomocysteinemia in uremia--a red flag in a disrupted circuit. *Seminars in Dialysis*, **2009**, 22, 351-6	2.5	33

220	Cytokines, atherogenesis, and hypercatabolism in chronic kidney disease: a dreadful triad. *Seminars in Dialysis*, **2009**, 22, 381-6	2.5	62
219	Leptin and uremic protein-energy wasting--the axis of eating. *Seminars in Dialysis*, **2009**, 22, 387-90	2.5	8
218	The role of oxidative stress in chronic kidney disease. *Seminars in Dialysis*, **2009**, 22, 405-8	2.5	96
217	Genetics/Genomics in chronic kidney disease--towards personalized medicine?. *Seminars in Dialysis*, **2009**, 22, 417-22	2.5	20
216	Conservative treatment of the uremic syndrome. *Seminars in Dialysis*, **2009**, 22, 449-53	2.5	1
215	Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients. *American Journal of Kidney Diseases*, **2009**, 54, 1072-80	7.4	64
214	Does the uremic milieu affect the epigenotype?. *Journal of Renal Nutrition*, **2009**, 19, 82-5	3	10
213	Metabolic abnormalities in chronic kidney disease that contribute to cardiovascular disease, and nutritional initiatives that may diminish the risk. *Current Opinion in Lipidology*, **2009**, 20, 3-9	4.4	22
212	Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation. *Molecular Medicine*, **2009**, 15, 70-5	6.2	43
211	Adiponectin in chronic kidney disease has an opposite impact on protein-energy wasting and cardiovascular risk: two sides of the same coin. *Clinical Nephrology*, **2009**, 72, 87-96	2.1	30
210	Cardiovascular Disease and Inflammation **2009**, 679-695		
209	Protein-Energy Malnutrition/Wasting During Peritoneal Dialysis **2009**, 611-647		2
208	Vascular Calcification in Chronic Kidney Disease **2009**, 697-711		2
207	Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease. *Journal of Nephrology*, **2009**, 22, 774-82	4.8	23
206	Low serum fetuin-A concentration predicts poor outcome only in the presence of inflammation in prevalent haemodialysis patients. *European Journal of Clinical Investigation*, **2008**, 38, 804-11	4.6	43
205	Telomere attrition is associated with inflammation, low fetuin-A levels and high mortality in prevalent haemodialysis patients. *Journal of Internal Medicine*, **2008**, 263, 302-12	10.8	137
204	Muscle atrophy, inflammation and clinical outcome in incident and prevalent dialysis patients. *Clinical Nutrition*, **2008**, 27, 557-64	5.9	185
203	Telomere biology alterations as a mortality risk factor in CKD. *American Journal of Kidney Diseases*, **2008**, 51, 1076-7	7.4	1

202	Modification of the oxidative stress biomarker AOPP assay: application in uremic samples. *Clinica Chimica Acta*, **2008**, 393, 114-8	6.2	44
201	Elevated serum levels of S-adenosylhomocysteine, but not homocysteine, are associated with cardiovascular disease in stage 5 chronic kidney disease patients. *Clinica Chimica Acta*, **2008**, 395, 106-10	6.2	49
200	Appetite disorders in uremia. *Journal of Renal Nutrition*, **2008**, 18, 107-13	3	75
199	Vascular calcification inhibitors in relation to cardiovascular disease with special emphasis on fetuin-A in chronic kidney disease. *Advances in Clinical Chemistry*, **2008**, 46, 217-62	5.8	26
198	Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. *Clinical Journal of the American Society of Nephrology: CJASN*, **2008**, 3, 976-85	6.9	92
197	Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2008**, 3, 61-8	6.9	96
196	Is UCP2 gene polymorphism associated with decreased resting energy expenditure in nondialyzed chronic kidney disease patients?. *Journal of Renal Nutrition*, **2008**, 18, 489-94	3	7
195	Aspects of immune dysfunction in end-stage renal disease. *Clinical Journal of the American Society of Nephrology: CJASN*, **2008**, 3, 1526-33	6.9	580
194	ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 388-95	12.7	70
193	Serum fetuin-a concentration and endothelial dysfunction in chronic kidney disease. *Nephron Clinical Practice*, **2008**, 108, c233-40		36
192	The role of the TGF/Smad signaling pathway in peritoneal fibrosis induced by peritoneal dialysis solutions. *Nephron Experimental Nephrology*, **2008**, 109, e71-8		38
191	Bone mineral density in end-stage renal disease patients: association with wasting, cardiovascular disease and mortality. *Blood Purification*, **2008**, 26, 284-90	3.1	17
190	Lipoprotein lipase 1595 c/g and hepatic lipase -480 c/t polymorphisms--impact on lipid profile in incident dialysis patients. *Blood Purification*, **2008**, 26, 555-60	3.1	2
189	Is fetuin-A/alpha2-Heremans-Schmid glycoprotein associated with the metabolic syndrome in patients with chronic kidney disease?. *American Journal of Nephrology*, **2008**, 28, 669-76	4.6	24
188	Epigenetics and the uremic phenotype: a matter of balance. *Contributions To Nephrology*, **2008**, 161, 55-62	1.6	11
187	Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. *Nephrology Dialysis Transplantation*, **2008**, 23, 1621-7	4.3	81
186	Interleukin-6 is a better predictor of mortality as compared to C-reactive protein, homocysteine, pentosidine and advanced oxidation protein products in hemodialysis patients. *Blood Purification*, **2008**, 26, 204-10	3.1	30
185	Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?. *Clinical Journal of the American Society of Nephrology: CJASN*, **2008**, 3, 505-21	6.9	380

184	Cytokine dysregulation in chronic kidney disease: how can we treat it?. *Blood Purification*, **2008**, 26, 291-9	3.1	76
183	The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality. *QJM - Monthly Journal of the Association of Physicians*, **2008**, 101, 397-405	2.7	52
182	Role of fat mass and adipokines in chronic kidney disease. *Current Opinion in Nephrology and Hypertension*, **2008**, 17, 25-31	3.5	43
181	Consequences of low plasma histidine in chronic kidney disease patients: associations with inflammation, oxidative stress, and mortality. *American Journal of Clinical Nutrition*, **2008**, 87, 1860-6	7	180
180	High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD). *Molecular Medicine*, **2008**, 14, 109-15	6.2	76
179	TOF-SIMS analysis of adipose tissue from patients with chronic kidney disease. *Applied Surface Science*, **2008**, 255, 1177-1180	6.7	25
178	Understanding the role of genetic polymorphisms in chronic kidney disease. *Pediatric Nephrology*, **2008**, 23, 1941-9	3.2	10
177	Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. *Nephrology Dialysis Transplantation*, **2008**, 23, 959-65	4.3	87
176	Resolved: being fat is good for dialysis patients: the Godzilla effect: con. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 1062-4	12.7	19
175	Statins to Treat Chronic Inflammation in Dialysis Patients Is this Feasible?. *Peritoneal Dialysis International*, **2007**, 27, 254-257	2.8	6
174	Malnutrition in Patients with End-Stage Renal Disease - Anorexia,Cachexia and Catabolism. *Current Nutrition and Food Science*, **2007**, 3, 37-46	0.7	1
173	Identifying and Managing Malnutrition Stemming from Different Causes. *Peritoneal Dialysis International*, **2007**, 27, 239-244	2.8	7
172	Reply to A Molfino et al. *American Journal of Clinical Nutrition*, **2007**, 86, 1551-1553	7	6
171	Impact of inflammation on epigenetic DNA methylation - a novel risk factor for cardiovascular disease?. *Journal of Internal Medicine*, **2007**, 261, 488-99	10.8	304
170	Polymorphisms in cytokine genes influence long-term survival differently in elderly male and female patients. *Journal of Internal Medicine*, **2007**, 262, 215-23	10.8	38
169	Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. *Journal of Internal Medicine*, **2007**, 262, 690-701	10.8	102
168	Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients. *Seminars in Dialysis*, **2007**, 20, 523-9	2.5	13
167	Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. *American Journal of Kidney Diseases*, **2007**, 49, 237-44	7.4	92

166	Changes in fat mass after initiation of maintenance dialysis is influenced by the uncoupling protein 2 exon 8 insertion/deletion polymorphism. *Nephrology Dialysis Transplantation*, **2007**, 22, 196-202	4.3	28
165	The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. *Nephrology Dialysis Transplantation*, **2007**, 22, 209-17	4.3	50
164	Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. *Clinical Journal of the American Society of Nephrology: CJASN*, **2007**, 2, 889-97	6.9	124
163	Association between oestrogen receptor alpha gene polymorphism and mortality in female end-stage renal disease patients. *Nephrology Dialysis Transplantation*, **2007**, 22, 2571-7	4.3	4
162	Influence of cytokine gene polymorphisms on erythropoetin dose requirements in chronic haemodialysis patients. *Nephrology Dialysis Transplantation*, **2007**, 22, 3586-92	4.3	12
161	Cytokine gene polymorphism and progression of renal and cardiovascular diseases. *Kidney International*, **2007**, 72, 549-56	9.9	69
160	Associations between the CYBA 242C/T and the MPO -463G/A polymorphisms, oxidative stress and cardiovascular disease in chronic kidney disease patients. *Blood Purification*, **2007**, 25, 210-8	3.1	15
159	Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. *American Journal of Clinical Nutrition*, **2007**, 85, 695-701	7	182
158	Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. *American Journal of Clinical Nutrition*, **2007**, 86, 633-8	7	204
157	OPTAInfluence of inflammation/infection on anaemia therapy in haemodialysis patients. *Nephrology Dialysis Transplantation*, **2007**, 22, iii7-iii12	4.3	4
156	Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors. *Clinica Chimica Acta*, **2007**, 379, 87-94	6.2	43
155	Insulin resistance is associated with circulating fibrinogen levels in nondiabetic patients receiving peritoneal dialysis. *Journal of Renal Nutrition*, **2007**, 17, 132-7	3	12
154	Use of single-nucleotide polymorphisms in the search for genetic modifiers of the uremic phenotype. *Journal of Renal Nutrition*, **2007**, 17, 17-22	3	6
153	Risk Factors for Cardiovascular Disease in Patients Undergoing Peritoneal Dialysis. *Peritoneal Dialysis International*, **2007**, 27, 205-209	2.8	36
152	Low-grade inflammation in chronic kidney disease patients before the start of renal replacement therapy: sources and consequences. *Clinical Nephrology*, **2007**, 68, 1-9	2.1	35
151	Oral health and pro-inflammatory status in end-stage renal disease patients. *Oral Health & Preventive Dentistry*, **2007**, 5, 235-44	1.9	14
150	Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. *American Journal of Kidney Diseases*, **2006**, 47, 139-48	7.4	371
149	J-shaped mortality relationship for uric acid in CKD. *American Journal of Kidney Diseases*, **2006**, 48, 761-71	7.4	172

148	Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD. *American Journal of Kidney Diseases*, **2006**, 48, 916-25	7.4	51
147	Adipose tissue and inflammation in chronic kidney disease. *Contributions To Nephrology*, **2006**, 151, 165-174	1.6	33
146	Peroxisome proliferator-activated receptor-gamma agonists diminish peritoneal functional and morphological changes induced by bioincompatible peritoneal dialysis solution. *Blood Purification*, **2006**, 24, 575-82	3.1	9
145	Imbalance between detached circulating endothelial cells and endothelial progenitor cells in chronic kidney disease. *Blood Purification*, **2006**, 24, 196-202	3.1	33
144	Being an inflamed peritoneal dialysis patient - a Dante's journey. *Contributions To Nephrology*, **2006**, 150, 144-151	1.6	16
143	Soluble adhesion molecules in end-stage renal disease: a predictor of outcome. *Nephrology Dialysis Transplantation*, **2006**, 21, 1603-10	4.3	54
142	C-reactive protein--does it promote vascular disease?. *Nephrology Dialysis Transplantation*, **2006**, 21, 2718-20	4.3	10
141	Adipokine signaling in the peritoneal dialysis patient. *Contributions To Nephrology*, **2006**, 150, 166-173	1.6	13
140	Statin treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2006**, 1, 281-7	6.9	33
139	Elevated serum 8-oxo-dG in hemodialysis patients: a marker of systemic inflammation?. *Antioxidants and Redox Signaling*, **2006**, 8, 2169-73	8.4	26
138	New insights on inflammation in chronic kidney disease-genetic and non-genetic factors. *Nephrologie Et Therapeutique*, **2006**, 2, 111-9	0.6	45
137	Effect of high-dose thiamine and pyridoxine on advanced glycation end products and other oxidative stress markers in hemodialysis patients: a randomized placebo-controlled study. *Journal of Renal Nutrition*, **2006**, 16, 119-24	3	19
136	Hyperhomocysteinemia, malnutrition, and inflammation in ESRD patients. *Seminars in Nephrology*, **2006**, 26, 14-9	4.8	5
135	Systemic and Intraperitoneal Interleukin-6 System during the First Year of Peritoneal Dialysis. *Peritoneal Dialysis International*, **2006**, 26, 53-63	2.8	88
134	Inflammation in end-stage renal disease: the hidden enemy. *Nephrology*, **2006**, 11, 36-41	2.2	140
133	Are insulin-like growth factor and its binding proteins 1 and 3 clinically useful as markers of malnutrition, sarcopenia and inflammation in end-stage renal disease?. *European Journal of Clinical Nutrition*, **2006**, 60, 718-26	5.2	37
132	Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. *Kidney International*, **2006**, 69, 596-604	9.9	168
131	Response to Resistin letters. *Kidney International*, **2006**, 70, 1372	9.9	

130	Place of genotyping and phenotyping in understanding and potentially modifying outcomes in peritoneal dialysis patients. *Kidney International*, **2006**, S138-45	9.9	9
129	Inflammation and wasting in chronic kidney disease: Partners in crime. *Kidney International*, **2006**, 70, S8-S13	9.9	54
128	Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. *Peritoneal Dialysis International*, **2006**, 26, 53-63	2.8	36
127	Interleukin-1 gene cluster polymorphisms are associated with nutritional status and inflammation in patients with end-stage renal disease. *Blood Purification*, **2005**, 23, 384-93	3.1	21
126	Inflammation in end-stage renal disease--a fire that burns within. *Contributions To Nephrology*, **2005**, 149, 185-199	1.6	65
125	Role of interleukin-1beta in the development of malnutrition in chronic renal failure patients. *Blood Purification*, **2005**, 23, 275-81	3.1	8
124	Homocysteine in uraemia--a puzzling and conflicting story. *Nephrology Dialysis Transplantation*, **2005**, 20, 16-21	4.3	116
123	Serum albumin: a late-reacting negative acute-phase protein in clinically evident inflammation in dialysis patients. *Nephrology Dialysis Transplantation*, **2005**, 20, 658-9; author reply 659-60	4.3	15
122	Enhanced RAGE-mediated NFkappaB stimulation in inflamed hemodialysis patients. *Atherosclerosis*, **2005**, 180, 333-40	3.1	59
121	Peroxisome proliferator-activated receptor gamma polymorphisms affect systemic inflammation and survival in end-stage renal disease patients starting renal replacement therapy. *Atherosclerosis*, **2005**, 182, 105-11	3.1	28
120	Why do dialysis patients develop a heart of stone and bone of china?. *Blood Purification*, **2005**, 23, 203-10	3.1	19
119	Adipose tissue and its relation to inflammation: the role of adipokines. *Journal of Renal Nutrition*, **2005**, 15, 131-6	3	91
118	Kidney insufficiency and nutrient-based modulation of inflammation. *Current Opinion in Clinical Nutrition and Metabolic Care*, **2005**, 8, 388-96	3.8	31
117	Gene polymorphism association studies in dialysis: the nutrition-inflammation axis. *Seminars in Dialysis*, **2005**, 18, 322-30	2.5	20
116	IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly. *Kidney International*, **2005**, 67, 1216-33	9.9	588
115	Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. *Kidney International*, **2005**, 67, 2383-92	9.9	232
114	Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. *Kidney International*, **2005**, 67, 2477-87	9.9	87
113	Increased muscle protein breakdown in chronic hemodialysis patients with type 2 diabetes mellitus. *Kidney International*, **2005**, 68, 1857-65	9.9	89

112	Accelerated lean body mass loss in incident chronic dialysis patients with diabetes mellitus. *Kidney International*, **2005**, 68, 2368-74	9.9	123
111	End-stage renal disease--not an equal opportunity disease: the role of genetic polymorphisms. *Journal of Internal Medicine*, **2005**, 258, 1-12	10.8	29
110	Multinutrient oral supplements and tube feeding in maintenance dialysis: a systematic review and meta-analysis. *American Journal of Kidney Diseases*, **2005**, 46, 387-405	7.4	125
109	Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD. *American Journal of Kidney Diseases*, **2005**, 46, 628-34	7.4	62
108	Chronic kidney disease and inflammation in pediatric patients: from bench to playground. *Pediatric Nephrology*, **2005**, 20, 714-20	3.2	37
107	Inflammation contributes to low plasma amino acid concentrations in patients with chronic kidney disease. *American Journal of Clinical Nutrition*, **2005**, 82, 342-349	7	56
106	Inflammation contributes to low plasma amino acid concentrations in patients with chronic kidney disease. *American Journal of Clinical Nutrition*, **2005**, 82, 342-9	7	46
105	Adipokines in Chronic Kidney Disease Fat Tissue Gives Nephrologists a Message. *Peritoneal Dialysis International*, **2005**, 25, 340-342	2.8	15
104	Circulating inflammatory endothelial cells contribute to endothelial progenitor cell dysfunction in patients with vasculitis and kidney involvement. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 3110-20	12.7	81
103	C-reactive protein in end-stage renal disease: are there reasons to measure it?. *Blood Purification*, **2005**, 23, 72-8	3.1	49
102	Is hyperhomocysteinemia a contributor to atherosclerosis in chronic kidney disease patients?. *Nephron Clinical Practice*, **2005**, 101, c187-9		2
101	Effect of hepatitis C serology on C-reactive protein in a cohort of Brazilian hemodialysis patients. *Brazilian Journal of Medical and Biological Research*, **2005**, 38, 783-8	2.8	26
100	Truncal fat mass as a contributor to inflammation in end-stage renal disease. *American Journal of Clinical Nutrition*, **2004**, 80, 1222-9	7	159
99	Chronic Inflammation in Peritoneal Dialysis: The Search for the Holy Grail?. *Peritoneal Dialysis International*, **2004**, 24, 327-339	2.8	76
98	Malnutrition and inflammation are associated with impaired pulmonary function in patients with chronic kidney disease. *Nephrology Dialysis Transplantation*, **2004**, 19, 1823-8	4.3	34
97	Impact of residual renal function on volume status in chronic renal failure. *Blood Purification*, **2004**, 22, 285-92	3.1	38
96	Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study. *Nephrology Dialysis Transplantation*, **2004**, 19, 421-6	4.3	97
95	Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy. *Nephrology Dialysis Transplantation*, **2004**, 19, 972-6	4.3	53

94	Improvement of cardiac function after haemodialysis. Quantitative evaluation by colour tissue velocity imaging. *Nephrology Dialysis Transplantation*, **2004**, 19, 1497-506	4.3	48
93	The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: a prospective study. *Nephrology Dialysis Transplantation*, **2004**, 19, 2803-9	4.3	52
92	The influence of hepatitis C and iron replacement therapy on plasma pentosidine levels in haemodialysis patients. *Nephrology Dialysis Transplantation*, **2004**, 19, 3112-6	4.3	17
91	Chronic systemic inflammation in dialysis patients: an update on causes and consequences. *ASAIO Journal*, **2004**, 50, lii-lvii	3.6	41
90	The Influence of C-Hepatitis on C-Reactive Protein in a Cohort of Brazilian Hemodialysis Patients. *Hemodialysis International*, **2004**, 8, 102-102	1.7	
89	Inflammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients. *Hemodialysis International*, **2004**, 8, 118-29	1.7	57
88	Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. *Kidney International*, **2004**, 65, 274-81	9.9	125
87	Reduced gene expression of adiponectin in fat tissue from patients with end-stage renal disease. *Kidney International*, **2004**, 66, 46-50	9.9	45
86	Novel approaches in an integrated therapy of inflammatory-associated wasting in end-stage renal disease. *Seminars in Dialysis*, **2004**, 17, 505-15	2.5	33
85	Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. *Scandinavian Journal of Urology and Nephrology*, **2004**, 38, 405-16		95
84	Hyperhomocysteinemia in relation to plasma free amino acids, biomarkers of inflammation and mortality in patients with chronic kidney disease starting dialysis therapy. *American Journal of Kidney Diseases*, **2004**, 44, 455-465	7.4	34
83	Chronic inflammation in peritoneal dialysis: the search for the holy grail?. *Peritoneal Dialysis International*, **2004**, 24, 327-39	2.8	29
82	Anaemia and inflammation: what are the implications for the nephrologist?. *Nephrology Dialysis Transplantation*, **2003**, 18 Suppl 8, viii17-22	4.3	27
81	The importance of diabetic nephropathy in current nephrological practice. *Nephrology Dialysis Transplantation*, **2003**, 18, 1716-25	4.3	42
80	Influence of Peritoneal Transport Rate, Inflammation, and Fluid Removal on Nutritional Status and Clinical Outcome in Prevalent Peritoneal Dialysis Patients. *Peritoneal Dialysis International*, **2003**, 23, 174-183	2.8	91
79	Association between residual renal function, inflammation and patient survival in new peritoneal dialysis patients. *Nephrology Dialysis Transplantation*, **2003**, 18, 590-7	4.3	95
78	Chronic inflammation in PD patients. *Contributions To Nephrology*, **2003**, 140, 104-11	1.6	7
77	Hyperhomocysteinemia and its relationship to cardiovascular disease in ESRD: influence of hypoalbuminemia, malnutrition, inflammation, and diabetes mellitus. *American Journal of Kidney Diseases*, **2003**, 41, S89-95	7.4	38

76	Associations between circulating inflammatory markers and residual renal function in CRF patients. *American Journal of Kidney Diseases*, **2003**, 41, 1212-8	7.4	319
75	Elevated cardiac troponin T in predialysis patients is associated with inflammation and predicts mortality. *Journal of Internal Medicine*, **2003**, 253, 153-60	10.8	45
74	Gene Expression Analysis in Inflamed and Non-inflamed Hemodialysis (HD) Patients Using a cDNA Microarray. *Hemodialysis International*, **2003**, 7, 73-104	1.7	
73	Review on uremic toxins: classification, concentration, and interindividual variability. *Kidney International*, **2003**, 63, 1934-43	9.9	1067
72	Beyond the membrane--the role of new PD solutions in enhancing global biocompatibility. *Kidney International*, **2003**, S124-32	9.9	8
71	A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. *Kidney International*, **2003**, S172-6	9.9	93
70	Genetic approaches in the clinical investigation of complex disorders: malnutrition, inflammation, and atherosclerosis (MIA) as a prototype. *Kidney International*, **2003**, S162-7	9.9	24
69	End-stage renal disease: a state of chronic inflammation and hyperleptinemia. *European Journal of Clinical Investigation*, **2003**, 33, 527-8	4.6	21
68	Interactions between inflammation, oxidative stress, and endothelial dysfunction in end-stage renal disease **2003**, 13, 144-8		59
67	Inflammation and nutrition in renal insufficiency. *Advances in Chronic Kidney Disease*, **2003**, 10, 155-69		78
66	Leptin, ghrelin, and proinflammatory cytokines: compounds with nutritional impact in chronic kidney disease?. *Advances in Chronic Kidney Disease*, **2003**, 10, 332-45		31
65	Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. *Nephrology Dialysis Transplantation*, **2003**, 18, 1272-80	4.3	540
64	Renal function in hypoxaemic chronic obstructive pulmonary disease: effects of long-term oxygen treatment. *Respiratory Medicine*, **2003**, 97, 308-16	4.6	15
63	Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. *Journal of the American Society of Nephrology: JASN*, **2003**, 14, 1927-39	12.7	182
62	Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. *Journal of the American Society of Nephrology: JASN*, **2003**, 14, 1614-22	12.7	117
61	Influence of peritoneal transport rate, inflammation, and fluid removal on nutritional status and clinical outcome in prevalent peritoneal dialysis patients. *Peritoneal Dialysis International*, **2003**, 23, 174-83	2.8	18
60	Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity. *American Journal of Kidney Diseases*, **2002**, 39, 274-82	7.4	167
59	What are the causes of protein-energy malnutrition in chronic renal insufficiency?. *American Journal of Kidney Diseases*, **2002**, 39, 422-5	7.4	19

58	Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy. *American Journal of Kidney Diseases*, **2002**, 40, 480-8	7.4	43
57	The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. *Kidney International*, **2002**, 62, 1524-38	9.9	846
56	Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage?. *Kidney International*, **2002**, 62, 1791-8	9.9	137
55	Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6?. *Kidney International*, **2002**, 103-8	9.9	134
54	Inflammation in end-stage renal disease: sources, consequences, and therapy. *Seminars in Dialysis*, **2002**, 15, 329-37	2.5	286
53	Soluble leptin receptors and serum leptin in end-stage renal disease: relationship with inflammation and body composition. *European Journal of Clinical Investigation*, **2002**, 32, 811-7	4.6	57
52	A comparative analysis of nutritional parameters as predictors of outcome in male and female ESRD patients. *Nephrology Dialysis Transplantation*, **2002**, 17, 1266-74	4.3	136
51	Inflammation, malnutrition and atherosclerosis in end-stage renal disease: a global perspective. *Blood Purification*, **2002**, 20, 454-8	3.1	43
50	Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. *Nephrology Dialysis Transplantation*, **2002**, 17, 1480-6	4.3	160
49	Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. *Nephrology Dialysis Transplantation*, **2002**, 17, 1684-8	4.3	290
48	The malnutrition, inflammation, and atherosclerosis (MIA) syndrome -- the heart of the matter. *Nephrology Dialysis Transplantation*, **2002**, 17 Suppl 11, 28-31	4.3	405
47	Inflammation in end-stage renal failure: could it be treated?. *Nephrology Dialysis Transplantation*, **2002**, 17 Suppl 8, 33-8; discussion 40	4.3	109
46	Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress. *Nephrology Dialysis Transplantation*, **2002**, 17 Suppl 5, 32-7	4.3	67
45	Molecular genetics in renal medicine: what can we hope to achieve?. *Nephrology Dialysis Transplantation*, **2002**, 17 Suppl 3, 5-11	4.3	17
44	Inflammatory and atherosclerotic interactions in the depleted uremic patient. *Blood Purification*, **2001**, 19, 53-61	3.1	168
43	Uremic Toxicity: Present State of the Art. *International Journal of Artificial Organs*, **2001**, 24, 695-725	1.9	209
42	Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. *Nephrology Dialysis Transplantation*, **2001**, 16, 2240-5	4.3	113
41	Malnutrition and chronic inflammation as risk factors for cardiovascular disease in chronic renal failure. *Blood Purification*, **2001**, 19, 143-51	3.1	119

40	Malnutrition, Inflammation, and Atherosclerosis in Peritoneal Dialysis Patients. *Peritoneal Dialysis International*, **2001**, 21, 157-162	2.8	76
39	Uremic toxicity: present state of the art. *International Journal of Artificial Organs*, **2001**, 24, 695-725	1.9	51
38	Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association with malnutrition, inflammation, and cardiovascular disease. *Nephrology Dialysis Transplantation*, **2000**, 15, 1624-30	4.3	140
37	Fat tissue accumulation during peritoneal dialysis is associated with a polymorphism in uncoupling protein 2. *Kidney International*, **2000**, 57, 1713-9	9.9	50
36	Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. *Kidney International*, **2000**, 57, 1727-35	9.9	145
35	LDL-apheresis in patients with nephrotic syndrome: effects on serum albumin and urinary albumin excretion. *European Journal of Clinical Investigation*, **2000**, 30, 866-70	4.6	18
34	Biocompatibility of New Peritoneal Dialysis Solutions: What Can We Hope to Achieve?. *Peritoneal Dialysis International*, **2000**, 20, 57-67	2.8	30
33	Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). *Nephrology Dialysis Transplantation*, **2000**, 15, 953-60	4.3	599
32	Physical activity promotes health also among dialysis patients. *International Journal of Cardiology*, **2000**, 72, 299-300	3.2	5
31	Hand-grip muscle strength, lean body mass, and plasma proteins as markers of nutritional status in patients with chronic renal failure close to start of dialysis therapy. *American Journal of Kidney Diseases*, **2000**, 36, 1213-25	7.4	203
30	Increases in serum leptin levels during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. *Journal of the American Society of Nephrology: JASN*, **2000**, 11, 1303-1309	12.7	138
29	Leptin and its clinical implications in chronic renal failure. *Mineral and Electrolyte Metabolism*, **1999**, 25, 298-302		24
28	Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure?. *Journal of Internal Medicine*, **1999**, 246, 503-7	10.8	94
27	Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. *Kidney International*, **1999**, 55, 1899-911	9.9	1196
26	High serum hyaluronan indicates poor survival in renal replacement therapy. *American Journal of Kidney Diseases*, **1999**, 34, 1083-8	7.4	58
25	The enigma of increasing serum leptin levels during peritoneal dialysis. *American Journal of Kidney Diseases*, **1999**, 34, 947-50	7.4	5
24	Molecular studies of leptin: implications for renal disease. *Nephrology Dialysis Transplantation*, **1999** , 14, 1103-12	4.3	33
23	Low leptin gene expression and hyperleptinemia in chronic renal failure. *Kidney International*, **1998**, 54, 1267-75	9.9	122

22	Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. *Kidney International*, **1998**, 53, 1336-42	9.9	56
21	Does the ob gene product leptin stimulate erythropoiesis in patients with chronic renal failure?. *Kidney International*, **1998**, 53, 1430-1	9.9	17
20	A study of plasmalogen as an index of oxidative stress in patients with chronic renal failure. Evidence of increased oxidative stress in malnourished patients. *Nephrology Dialysis Transplantation*, **1998**, 13, 2594-600	4.3	61
19	Hormonal status in critically ill patients with or without acute renal failure **1998**, 391-403		
18	A calcium-channel blocker, amlodipine, attenuates insulin antinatriuresis but does not modulate insulin-mediated attenuation of cardiovascular reactivity in healthy man. *Nephrology Dialysis Transplantation*, **1997**, 12, 1600-7	4.3	
17	Influence of variation at the apolipoprotein E locus on lipid and lipoprotein levels in CAPD patients. *Nephrology Dialysis Transplantation*, **1997**, 12, 141-4	4.3	19
16	Serum leptin concentrations correlate to plasma insulin concentrations independent of body fat content in chronic renal failure. *Nephrology Dialysis Transplantation*, **1997**, 12, 1321-5	4.3	85
15	Short-term treatment with ramipril normalizes renal haemodynamics and the natriuretic response to a sodium load in type 1 diabetic patients with early nephropathy. *Acta Diabetologica*, **1997**, 34, 10-7	3.9	2
14	Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome. *European Journal of Clinical Investigation*, **1997**, 27, 169-77	4.6	16
13	Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. *Journal of the American Society of Nephrology: JASN*, **1997**, 8, 1423-30	12.7	154
12	Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose. *Nephron*, **1996**, 72, 135-44	3.3	48
11	Lipoprotein(a) in chronic renal disease. *Mineral and Electrolyte Metabolism*, **1996**, 22, 16-21		3
10	Effect of insulin on renal sodium handling and renal haemodynamics in insulin-dependent (type 1) diabetes mellitus patients. *Acta Diabetologica*, **1995**, 32, 230-4	3.9	6
9	Renal hemodynamics and sodium handling in moderate renal insufficiency: the role of insulin resistance and dyslipidemia. *Journal of the American Society of Nephrology: JASN*, **1995**, 5, 1751-60	12.7	27
8	Insulin causes renal vasodilatation independently of renal prostaglandins in healthy humans. *Nephrology Dialysis Transplantation*, **1994**, 9, 1728-33	4.3	5
7	Lipoprotein(a) in nephrotic syndrome. *Kidney International*, **1993**, 44, 1116-23	9.9	47
6	Renal haemodynamics and tubular sodium handling following volume expansion with sodium chloride (NaCl) and glucose in healthy humans. *Scandinavian Journal of Clinical and Laboratory Investigation*, **1992**, 52, 837-46	2	17
5	Effects of insulin on renal haemodynamics and the proximal and distal tubular sodium handling in healthy subjects. *Diabetologia*, **1992**, 35, 1042-8	10.3	87

4	Decreased renal clearance of sodium in cystic fibrosis. *Acta Paediatrica, International Journal of Paediatrics*, **1991**, 80, 194-8	3.1	16
3	Impaired intrarenal dopamine production following intravenous sodium chloride infusion in type 1 (insulin-dependent) diabetes mellitus. *Diabetologia*, **1991**, 34, 114-8	10.3	25
2	Factors influencing progression in patients with chronic renal failure. *Journal of Internal Medicine*, **1989**, 226, 183-8	10.8	17
1	Clostridium difficile-associated diarrhoea in uremic patients. *European Journal of Clinical Microbiology and Infectious Diseases*, **1987**, 6, 352-6	5.3	29